Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications

References

• Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann. Intern. Med.148, 16–29 (2008).
   PubMed Web of Science ®Google Scholar
• Balcells E, Meng QC, Johnson WH Jr et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am. J. Physiol.273, H1769–H1774 (1997).
   PubMed Web of Science ®Google Scholar
• Ihara M, Urata H, Kinoshita A et al. Increased chymase dependent angiotensin II formation in human atherosclerotic aorta. Hypertension33, 1399–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Jorde UP, Ennezat PV, Lisker J et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation101, 844–846 (2000).
   PubMed Web of Science ®Google Scholar
• Cao Z, Kelly DJ, Cox AJ et al. The angiotensin type 2 receptor is expressed in adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int.58, 2437–2451 (2000).
   PubMed Web of Science ®Google Scholar
• Sandmann S, Unger T. Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure. Drugs62(Spec. No. 1), 43–52 (2002).
   PubMed Web of Science ®Google Scholar
• Esteban V, Lorenzo O, Ruiperez M et al. Angiotensin II, via AT1 and AT2 receptors and NF-κB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J. Am. Soc. Nephrol.15, 1514–1529 (2004).
   PubMed Web of Science ®Google Scholar
• Juillerat L, Nussberger J, Menard J et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension16, 564–572 (1990).
   PubMed Web of Science ®Google Scholar
• Cao Z, Bonnet F, Candido R et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J. Am. Soc. Nephrol.13, 1773–1787 (2002).
   PubMed Web of Science ®Google Scholar
• Azizi M, Chatellier G, Guyene TT et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation92, 825–834 (1995).
   PubMed Web of Science ®Google Scholar
• Azizi M, Guyene TT, Chatellier G et al. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension29, 634–640 (1997).
   PubMed Web of Science ®Google Scholar
• Azizi M, Linhart A, Alexander J et al. Pilot study of combined blockade of the renin–angiotensin system in essential hypertensive patients. J. Hypertens.18, 1139–1147 (2000).
   PubMed Web of Science ®Google Scholar
• Stergiou GS, Skeda I, Baibas NM et al. Additive hypotensive effect of angiotensin concerting enzyme inhibition and angiotensin receptor antagonism in essential Hypertension. J. Cardiovasc. Pharmacol.35, 937–941 (2000).
   PubMed Web of Science ®Google Scholar
• Ruiz Ortega M, Lorenzo O, Ruiperez M, Koning S, Witting B, Egido J. Angiotensin II activates nuclear transcription factor κB through AT(1) and AT(2) in vascular smooth mucle cells: molecular mechanisms. Circ. Res.86, 1266–1272 (2000).
   PubMed Web of Science ®Google Scholar
• Guijarro C, Egido J. Transcription factor κB (NF-κB) and renal disease. Kidney Int.59, 415–424 (2001).
   PubMed Web of Science ®Google Scholar
• Bonnet F, Cooper ME, Kawachi H et al. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and Hypertension. Diabetologia44, 874–877 (2001).
   PubMed Web of Science ®Google Scholar
• Benigni A, Tomasoni S, Gagliardini E et al. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J. Am. Soc. Nephrol.12, 941–948 (2001).
   PubMed Web of Science ®Google Scholar
• The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet349, 1857–1863 (1997).
   PubMed Web of Science ®Google Scholar
• Fernandez-Juarez G, Barrio V, Garcia de Vinuesa S, Goicoechea M, Praga M, Luno J. Dual blockade of renin–angiotensin system in the progression of renal disease: the need for more clinical trials. J. Am. Soc. Nephrol.17, S250–S254 (2006).
   Google Scholar
• Campbell R, Sangalli F, Perticucci E et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int.63, 1094–1103 (2003).
   PubMed Web of Science ®Google Scholar
• Ruilope L, Aldigier J, Ponticelli C, Oddou-Stock P, Botteri F, Mann J; European Group for the Investigation of Valsartan in Chronic Renal Disease. Safety of the combination of valsartan and benazepril in patients with chronic kidney disease. J. Hypertens.18, 89–95 (2000).
   PubMed Web of Science ®Google Scholar
• Berger E, Bader B, Ebert C, Risler C, Erley C. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme. J. Hypertens.20, 739–743 (2002).
   PubMed Web of Science ®Google Scholar
• Laverman G, Navis G, Henning R, de Jong P, Zeeuw D. Dual rennin–angiotensin system blockade at optimal doses for proteinuria. Kidney Int.62, 1020–1025 (2002).
   PubMed Web of Science ®Google Scholar
• Luño J, Barrio V, Goicoechea M et al. Effects of dual blockade of the rennin–angiotensin system in primary proteinuric nephropathies. Kidney Int.62(Suppl. 82), S47–S52 (2002).
   Google Scholar
• Ferrari P, Marti H, Pfister M, Frey F. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J. Hypertens.20, 125–130 (2002).
   PubMed Web of Science ®Google Scholar
• Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination Treatment of Angiotensin-II Receptor Blocker and Angiotensin-Converting-Enzyme Inhibitor in Non-Diabetic Renal Disease (COOPERATE): a randomized controlled trial. Lancet361, 117–124 (2003).
   PubMed Web of Science ®Google Scholar
• Bidani A. Controversy about COOPERATE ABPM trial data. Am. J. Nephrol.26, 629–632 (2006).
   PubMedGoogle Scholar
• Jacobsen P, Andersen S, Rossing K, Hansen B, Parving H. Dual blockade of the rennin–angiotensin system in Type 1 patients with nephropathy. Nephrol. Dial. Transplant.17, 1019–1024 (2002).
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Andersen S, Jensen B, Parving H. Additive effect of ACE inhibition and angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy. J. Am. Soc. Nephrol.14, 992–999 (2003).
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Andersen S, Rossing K, Jensen B, Parving H. Dual blockade of the renin–angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int.63, 1874–1880 (2003).
   PubMed Web of Science ®Google Scholar
• Mogensen C, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of rennin–angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes:the candesartan and lisinopril microalbuminuria (CALM) study. BMJ321, 1440–1444 (2000).
   PubMed Web of Science ®Google Scholar
• Rossing K, Christensen P, Jensen B, Parving H. Dual blockade of the renin–angiotensin system in diabetic nephropathy. Diabetes Care25, 95–100 (2002).
   PubMed Web of Science ®Google Scholar
• Kuntz R, Friedrich C, Wolbers M, Mann J. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin–angiotensin system on proteinuria in renal disease. Ann. Intern. Med.148, 30–48 (2008).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB et al.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet362(9386), 759–766 (2003).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blokers valsartan in chronic heart failure. N. Engl. J. Med.345, 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol.39, 463–470 (2002).
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet362(9386), 767–771 (2003).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med.349 (20), 1893–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Cleland J, Dargie H et al. The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J.26(11), 1115–1140 (2005).
   PubMed Web of Science ®Google Scholar
• Phillips C, Kashani A, Ko D. Adverse effect of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction. Arch. Intern. Med.167(18), 1930–1936 (2007).
   PubMed Web of Science ®Google Scholar
• The Task Force for the Management of arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J. Hypertens.25, 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Chobanian A, Bakris G, Black H et al. National Heart, Lung and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42, 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Kincaid-Smith P, Fairley KF, Packham D. Dual blockade of the renin–angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. Nephrol. Dial. Transplant.19, 2272–2274 (2004).
   PubMed Web of Science ®Google Scholar
• Knudsen S, Andersen N, Poulsen S et al. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ace inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. Am. J. Hypertens.21(2), 172–176 (2008).
   PubMed Web of Science ®Google Scholar
• Izzo JL Jr, Weinberg MS, Hainer JW, Kerkering J, Tou CK; AMAZE. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J. Clin. Hypertens.6(9), 485–493 (2004).
   PubMedGoogle Scholar
• Weir MR, Smith DHG, Neutel JM, Bedigian MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am. J. Hypertens.14, 665–671 (2001).
   PubMedGoogle Scholar
• Forclaz A, Maillard M, Nussberger J et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension41, 31–36 (2003).
   PubMed Web of Science ®Google Scholar
• Doulton TWR, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension45, 880–886 (2005).
   PubMed Web of Science ®Google Scholar
• Stergiou GS, Makris T, Papavasiliou M, Efstathiou S, Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J. Hypertens.23, 883–889 (2005).
   PubMed Web of Science ®Google Scholar
• Grandi A, Solbiati F, Laurita E et al. Effects of dual blockade of renin–angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study. Am. J. Hypertens.21, 231–237 (2008).
   PubMed Web of Science ®Google Scholar
• Andersen NH, Poulsen PI, Knudsen ST et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. Diabetes Care28, 273–277 (2005).
   PubMed Web of Science ®Google Scholar
• van de Wal RMA, van Veldhuisen DJ, van Gilst WH, Voors AA. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur. Heart J.26, 2361–2367 (2005).
   PubMed Web of Science ®Google Scholar
• McMurray J, Solomon S, Pieper K et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J. Am. Coll. Cardiol.47, 726–733 (2006).
   PubMed Web of Science ®Google Scholar
• Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation114, 838–854 (2006).
   PubMed Web of Science ®Google Scholar
• The Heart Outcomes Prevention Evaluation Study (HOPE) investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• Teo K, Yusuf S, Sleight P et al.; ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J.148, 52–61 (2004).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulszewski A. et al. Morbidity and Mortality after Stroke – Eprosartan Compared With Nitrendypine for Secondary Prevention (MOSES). Stroke36, 1218–1226 (2005).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Fournier A, Messerli F, Achard J, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized trial. J. Am. Coll. Cardiol.43, 1343–1347 (2004).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever P, Poulter N et al. The ASCOT investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering ARM ( ASCOT-BPLA); a multicentre randomized controlled trial. Lancet366, 895–906 (2005).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intevention For Endpoint reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1008 (2002).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodypine: the VALUE randomized trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar